BioFactura recently announced the addition of two new members to their team. Hallison Rodrigue and Trevor Zimmerman both join as Quality Control Analyst IIIs.
BioFactura Welcomes New Team Members
Biosimilars Market is Fertile Ground for Impact Investors
An impact investor can be an individual or investment fund that has co-equal primary goals: to make money and foment positive social change that can last. In some ways, impact investors are “social VCs”—they fund projects and companies that can create positive, measurable impact for the greater good of humanity. Unlike traditional VC investment strategies that tend to take a high risk, high reward approach, impact investing generally focuses on lower risk, more modest or conservative financial investments that yield the most possible good for people and communities.
Despite Strong 2021 Performance Headwinds Remain for Biosimilars Uptake
Biosimilars, also known as follow-on biologics, continued to capture greater market share and foment stronger competition with reference or brand name drugs in 2021. Increasing the number of biosimilars in the market and amplifying uptake by payers, family medical practices and pharmacies could be a gamechanger for patients and a healthcare system trying to reduce the cost of life-changing medicines.
Biomanufacturing Career Tips for a Booming Life Sciences Market
WorkForce Genetics recently hosted the webinar event, “Navigating Your Biomanufacturing Career.” The webinar, which was held in March 2022, brought together industry thought leaders for a robust panel discussion about biomanufacturing career tips for the BioHealth Capital Region’s booming job market.
Doogie and the Rock Star: BioFactura’s Remarkable Journey
BioFactura, a leading developer and manufacturer of biosimilars and biodefense products, is one of the crown jewels of Frederick, Maryland’s growing biotech hub. The company is thriving and has secured strong funding from both private and government sources that see the potential of the company’s StableFast™ biosimilars platform. In May 2021, BioFactura reached an important milestone, announcing that it had moved its first biosimilar product into the clinic.
Biosimilars Company, BioFactura, Announces Significant Team Growth
In a rapidly expanding market, BioFactura is making waves in a big way in 2021. From initiation of a phase 1 study for a biosimilar treatment for people suffering from Crohn’s Disease to a recent transfer agreement with RANI Therapeutics, there’s a lot to be excited about for a company of just under 50 employees.
The Benefits of Taking Your Career to a Growth Stage Biotech
Over the next few years, thousands of new positions in the biopharma and life sciences industry are expected to open up across the BioHealth Capital Region and the greater Philadelphia area known as Cellicon Valley.
Whether you are fresh out of the university or a seasoned veteran, many job seekers question whether or not they should aim for large biopharmaceutical companies, such as AstraZeneca, Pfizer or GlaxoSmithKline, or look at nimble, growth-stage companies, such as American Gene Technologies, Vita Therapeutics, or BioFactura, Inc., which is currently scaling their cGMP and Quality operations.
BioFactura is on Course to Become a Global Leader in Biosimilar Development
Since the approval of the first biosimilar drug in the United States six years ago, the market has rapidly expanded and is expected to grow to approximately $23 billion in the U.S. by 2027. And Maryland’s BioFactura anticipates it will be one of the companies at the forefront of this revolution of new medications.
BioFactura Announces MTA with Rani Therapeutics
BioFactura Inc. (“BioFactura”), a leading developer of high-value biosimilar and biodefense drugs using its patented StableFast™ platform, announces an agreement with Rani Therapeutics (“Rani”) to assess its Ustekinumab Biosimilar (BFI-751) in combination with Rani’s RaniPill™ platform.
BioFactura Announces Initiation of Phase I Study of BFI-751, a Stelara® (ustekinumab) Biosimilar
BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®. This is the first time BFI-751 has been administered to humans, as authorized by the Ethics Committees in both Australia and New Zealand.